{"name":"Pearl Therapeutics, Inc.","slug":"pearl-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"immunology","drugs":[{"name":"FF MDI (PT005)","genericName":"FF MDI (PT005)","slug":"ff-mdi-pt005","indication":"Asthma maintenance treatment","status":"phase_3"},{"name":"GP MDI (PT001)","genericName":"GP MDI (PT001)","slug":"gp-mdi-pt001","indication":"Maintenance treatment of asthma","status":"phase_3"},{"name":"Symbicort Turbohaler","genericName":"Symbicort Turbohaler","slug":"symbicort-turbohaler","indication":"Maintenance and relief of asthma symptoms","status":"phase_3"},{"name":"Symbicort® Turbohaler® Inhalation Powder","genericName":"Symbicort® Turbohaler® Inhalation Powder","slug":"symbicort-turbohaler-inhalation-powder","indication":"Maintenance and relief of asthma symptoms","status":"phase_3"},{"name":"BD MDI 160 µg","genericName":"BD MDI 160 µg","slug":"bd-mdi-160-g","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"BD MDI 40 µg","genericName":"BD MDI 40 µg","slug":"bd-mdi-40-g","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"BD MDI 80 µg","genericName":"BD MDI 80 µg","slug":"bd-mdi-80-g","indication":"Asthma maintenance therapy","status":"phase_2"},{"name":"BFF MDI (PT009)","genericName":"BFF MDI (PT009)","slug":"bff-mdi-pt009","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"BGF MDI (PT010)","genericName":"BGF MDI (PT010)","slug":"bgf-mdi-pt010","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_3"},{"name":"FF MDI","genericName":"FF MDI","slug":"ff-mdi","indication":"Asthma maintenance treatment","status":"phase_3"},{"name":"GFF MDI","genericName":"GFF MDI","slug":"gff-mdi","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"GFF MDI (PT 003)","genericName":"GFF MDI (PT 003)","slug":"gff-mdi-pt-003","indication":"Maintenance treatment of asthma","status":"phase_3"},{"name":"GP MDI","genericName":"GP MDI","slug":"gp-mdi","indication":"Asthma maintenance treatment","status":"phase_3"},{"name":"Glycopyrronium MDI","genericName":"Glycopyrronium MDI","slug":"glycopyrronium-mdi","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"Glycopyrronium MDI 7.2 micrograms","genericName":"Glycopyrronium MDI 7.2 micrograms","slug":"glycopyrronium-mdi-7-2-micrograms","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"Ipratropium Bromide HFA Inhalation Aerosol","genericName":"Ipratropium Bromide HFA Inhalation Aerosol","slug":"ipratropium-bromide-hfa-inhalation-aerosol","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"AZD 2115, Dose 2","genericName":"AZD 2115, Dose 2","slug":"azd-2115-dose-2","indication":"Other","status":"phase_2"},{"name":"AZD2115 Dose 1","genericName":"AZD2115 Dose 1","slug":"azd2115-dose-1","indication":"Other","status":"phase_2"},{"name":"Glycopyrronium MDI 14.4 micrograms","genericName":"Glycopyrronium MDI 14.4 micrograms","slug":"glycopyrronium-mdi-14-4-micrograms","indication":"Other","status":"phase_2"},{"name":"PT001","genericName":"PT001","slug":"pt001","indication":"Other","status":"phase_2"},{"name":"Tiotropium Handihaler","genericName":"Tiotropium Handihaler","slug":"tiotropium-handihaler","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AZD 2115, Dose 2","genericName":"AZD 2115, Dose 2","slug":"azd-2115-dose-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"FF MDI (PT005)","genericName":"FF MDI (PT005)","slug":"ff-mdi-pt005","phase":"phase_3","mechanism":"FF MDI is a combination inhaled corticosteroid (fluticasone propionate) and long-acting beta-2 agonist (formoterol) metered-dose inhaler for maintenance treatment of asthma and COPD.","indications":["Asthma maintenance treatment","Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"GP MDI (PT001)","genericName":"GP MDI (PT001)","slug":"gp-mdi-pt001","phase":"phase_3","mechanism":"PT001 is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via metered-dose inhaler for maintenance treatment of asthma and COPD.","indications":["Maintenance treatment of asthma","Maintenance treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Symbicort Turbohaler","genericName":"Symbicort Turbohaler","slug":"symbicort-turbohaler","phase":"phase_3","mechanism":"Symbicort Turbohaler is a combination of budesonide and formoterol, a corticosteroid and a long-acting beta2-adrenergic receptor agonist, respectively, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).","indications":["Maintenance and relief of asthma symptoms","Maintenance treatment of COPD"],"catalyst":""},{"name":"Symbicort® Turbohaler® Inhalation Powder","genericName":"Symbicort® Turbohaler® Inhalation Powder","slug":"symbicort-turbohaler-inhalation-powder","phase":"phase_3","mechanism":"Symbicort is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).","indications":["Maintenance and relief of asthma symptoms","Maintenance treatment of COPD"],"catalyst":""},{"name":"AZD2115 Dose 1","genericName":"AZD2115 Dose 1","slug":"azd2115-dose-1","phase":"phase_2","mechanism":"AZD2115 is an investigational drug with an undisclosed mechanism of action.","indications":[],"catalyst":""},{"name":"BD MDI 160 µg","genericName":"BD MDI 160 µg","slug":"bd-mdi-160-g","phase":"phase_2","mechanism":"BD MDI 160 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD.","indications":["Maintenance treatment of asthma","Maintenance treatment of COPD"],"catalyst":""},{"name":"BD MDI 40 µg","genericName":"BD MDI 40 µg","slug":"bd-mdi-40-g","phase":"phase_2","mechanism":"BD MDI 40 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD.","indications":["Maintenance treatment of asthma","Maintenance treatment of COPD"],"catalyst":""},{"name":"BD MDI 80 µg","genericName":"BD MDI 80 µg","slug":"bd-mdi-80-g","phase":"phase_2","mechanism":"BD MDI 80 µg is a budesonide/formoterol combination inhaler that reduces airway inflammation and improves bronchodilation for respiratory disease management.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BFF MDI (PT009)","genericName":"BFF MDI (PT009)","slug":"bff-mdi-pt009","phase":"phase_3","mechanism":"BFF MDI is a combination inhaled therapy containing budesonide, formoterol, and glycopyrronium that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"BGF MDI (PT010)","genericName":"BGF MDI (PT010)","slug":"bgf-mdi-pt010","phase":"phase_3","mechanism":"BGF MDI is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"FF MDI","genericName":"FF MDI","slug":"ff-mdi","phase":"phase_3","mechanism":"FF MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist for maintenance treatment of asthma and COPD.","indications":["Asthma maintenance treatment","Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"GFF MDI","genericName":"GFF MDI","slug":"gff-mdi","phase":"phase_3","mechanism":"GFF MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in obstructive airway diseases.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"GFF MDI (PT 003)","genericName":"GFF MDI (PT 003)","slug":"gff-mdi-pt-003","phase":"phase_3","mechanism":"GFF MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via metered-dose inhaler for maintenance treatment of asthma and COPD.","indications":["Maintenance treatment of asthma","Maintenance treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"GP MDI","genericName":"GP MDI","slug":"gp-mdi","phase":"phase_3","mechanism":"GP MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via metered-dose inhaler for maintenance treatment of asthma and COPD.","indications":["Asthma maintenance treatment","Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"Glycopyrronium MDI","genericName":"Glycopyrronium MDI","slug":"glycopyrronium-mdi","phase":"phase_2","mechanism":"Anticholinergic","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Glycopyrronium MDI 14.4 micrograms","genericName":"Glycopyrronium MDI 14.4 micrograms","slug":"glycopyrronium-mdi-14-4-micrograms","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glycopyrronium MDI 7.2 micrograms","genericName":"Glycopyrronium MDI 7.2 micrograms","slug":"glycopyrronium-mdi-7-2-micrograms","phase":"phase_2","mechanism":"Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to bronchodilation.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Ipratropium Bromide HFA Inhalation Aerosol","genericName":"Ipratropium Bromide HFA Inhalation Aerosol","slug":"ipratropium-bromide-hfa-inhalation-aerosol","phase":"phase_2","mechanism":"Anticholinergic agent that inhibits muscarinic acetylcholine receptors","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"PT001","genericName":"PT001","slug":"pt001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tiotropium Handihaler","genericName":"Tiotropium Handihaler","slug":"tiotropium-handihaler","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPN3RqNDBQSHBleFRCbDVMaWQ2ZU9fcFp0RnI5aG8wNzN1MFg0ZmpHX0VpRkp0MGpHMHRUQzhnMjdkTDJ2MVNTNTh4QXp1dXBiM1FHWFMzWGJiMG10OVZtRktQaWt2MzFpMkxNR1UycXBtRHU2eGhzaEVPVDh4aGdxMEs0VmY3RXI3ZC01ajZRRXhBZTM4SGxJNWJhLWU0aS1IYmpEVzFvV0hRRTItSHhMZUhla2phcEdrUFlR?oc=5","date":"2025-02-06","type":"pipeline","source":"indica News","summary":"Indian American CEO Sarvajna Dwivedi Driven to Revolutionize Blocked Artery Treatment - indica News","headline":"Indian American CEO Sarvajna Dwivedi Driven to Revolutionize Blocked Artery Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxQUlBEN2JQMkVlejVsUDE0d0pQcXhDTHBHdE1nMmhzTVNERFBfTDkzWW83Yi1ZZEpBbHowUjA1S0VpNnJ2NXZnUHRJY09NUDVxZnp2WFNxc1I2Q0x3dTFldXhFNm5JUDR5MlA4a0tDeTUxYm5WYTZMVzZUczJHYjBHbDFFaDRiTDZTSlJNRzFnbHBjNUYwNkR3ejJGa3AweDlpeVdhdk5ucGJmSHctSTdHS3g5N2lMYU1fMDB3TlYtUlBScG4zYUI4bk5LQjVlaGt3blZ5OWRfdkVCY2NFcWYtZ1UxVGxrZWJtZExQSGxFYUN4c1ZSQWhaZkxhT1M1RXRudlNuRXNlMXQ3MzFPMkZTeFRvS3VVaHprWlpsazd1akZOUQ?oc=5","date":"2024-11-06","type":"trial","source":"prnewswire.com","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - prnewswire.com","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPZFV5cmRKNzBhSzhjcHJMczZqVDNnc3Q3U0N2elFEblI5QUsxdF9fSW9EWmxmUWNFcTdlbEpIdFBkYy01RDBzbFRoOEhJQ1htNl9maGJOc2E4bXUwdDZaVDZpT1lnQnhydmRqdVRFNmZNM1FfSGgxclE5UWhzcl9aREQ5QQ?oc=5","date":"2024-10-08","type":"pipeline","source":"Yahoo Finance","summary":"Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree - Yahoo Finance","headline":"Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQVktkODdKdWx2X1FxVTFLdnRVVXpOSEY2d0xDU3VZdHpDbTBZOHNleXlGTjR5TTJ3R2t1a3ZzSWxQU2U1a1d4YUZXU0xtYWRRd3RxZHpJV0RCUWlOdm5tQTg1aEZPMF9OcE10UnFTYjBzWGstNUhRelVwRm8yV3k5ZDdwV29sSm1Vck9XUi1STWtaeUFaUzhHa3JJQ2poTWJIdmNLa1FIMndxMXlmNWFxSlozMHFaaS1jdk9hVXVCTUVCZXlsWWNjcFU4UjdjUmJwOU1UblVsQ2tWMU8zVnFWbll1SkJfVF83?oc=5","date":"2024-04-08","type":"pipeline","source":"The Journal News | lohud.com","summary":"Pearl River-based Acorda Therapeutics to close; 97 jobs impacted - The Journal News | lohud.com","headline":"Pearl River-based Acorda Therapeutics to close; 97 jobs impacted - The Journal News | lohud.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPd0NCQ0dDajR3YnVOeFVRTGtBS1l6dlFGN3NteGZ4dm93OTlCYTBVX2dtb3ZYaDJOX0JadEV6WXFXdkJQNW1udHRnbjNVRkFIczFnN0NRU3J0MXRJRXVWV2JWMjRWQUpZY09Cc2ZsQXlxVEZKaWFHUWp5RE16VTNPeGpBRDB6V2VWOWRkZ2NvN3RZZjQ?oc=5","date":"2024-03-12","type":"pipeline","source":"BioSpace","summary":"Merck Bets Potential $1B on Pearl Bio’s Genomically Recoded Organisms - BioSpace","headline":"Merck Bets Potential $1B on Pearl Bio’s Genomically Recoded Organisms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPem9yLXFvQld5ZElRUDJxNm1WU0ltWl9zcmhWSFdQRjJGWkxFRkJFWGEtT0V2b1hBN0NSYXhyUWJvb0tYS2ZvZTFaNWo3WFNORlBGU3BjU3d3QTJ4SWkyM1hVYWRQU0wwZHpqcGROc0JoT2Z1a1M1RFEwRmN4QTZZNnVwRk9vTWVJbDFwdFVvaEVacFpTNTVyS0NXSEN4Y1E4VEdYMXlkdTYxdWxNc1ZIVFY5Z1h2dGhaN0k1YldTMkxweHhv?oc=5","date":"2023-12-15","type":"deal","source":"respiratory-therapy.com","summary":"AstraZeneca to Acquire Pearl Therapeutics - respiratory-therapy.com","headline":"AstraZeneca to Acquire Pearl Therapeutics - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQUXRfRWQzTFppejN1MkthYjdqNDNmU2llOGVTbHBPVUhjZU5fVW5XN3FwWmFQLWcyZEstUkp3YXNrYjNBaEgybWdFRXlzT2JLSlJMclJaTVZBNGxQVjBVNHg5U2tjeVFhc0dKdkhBWjRQdFNsVDdfN3RGOUttT212NFEyYzY2ZHlxaUIxU3pWNENiOVViQ0pabHpaaEx2Q1JSX0tYRy05RHFCQ1Qyc1g0Zm1EcU44MVB3OUl4aThTc2JSTGJ0OEdhVnB2OFBVWlNTWlp0MzRrc3hSS25ETmdLUC1oMEJSel9xbGZ3RE9vYl82SFU?oc=5","date":"2023-11-27","type":"pipeline","source":"respiratory-therapy.com","summary":"Pearl Therapeutics’ PT001 Demonstrates Positive Results in Patients with COPD - respiratory-therapy.com","headline":"Pearl Therapeutics’ PT001 Demonstrates Positive Results in Patients with COPD - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNX21TYXkwVmJOSG9LSlFaOWtlMUFPYlFnOHZXMlZCWEFpWnNubVU5TVE0clhEa3YzYmRWUTlRVHNuYko2SUdSakZCU1BwZVRpZ29TMnZYTFNQT3M3UGlDQnhRQklocGRXNjVOSjM4eUhCc1RoOFphX2xXR3NTM0JSbFE1c0FPTXRnQXNkdWM2YzBRZHpWZDAwb1ZKWG81ci1Pdjd5YnhyT1RsZ21VRHVCbWJWZGkyOVVWY2c?oc=5","date":"2022-10-17","type":"pipeline","source":"businesswire.com","summary":"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer - businesswire.com","headline":"Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQTEZJNHVLY2swZmQ5ZzI2djYxaHRRc0g1TzlWVWEtMWh1Z1ZqNjN1dE0zUlpwb0dpbTh0UmR1YVpFbVV3STBPUzVEXzV5dmhMRGxsckFMRTBZcmxkZ2hQUW1ubEwyend2dUhDSDhSc3ZDX1ZTNGh3YVFHZTdELTNZNWFjeTZETHZIdUVRbG9NeTFSVEtqVVpPc05B?oc=5","date":"2021-09-13","type":"pipeline","source":"Fierce Biotech","summary":"Where are they now? Tracking down 2011’s Fierce 15 - Fierce Biotech","headline":"Where are they now? Tracking down 2011’s Fierce 15","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNenRULU1FU0szTEh2NVVySFdHVVp1Zkt5Tk16NjBQSW5teVJDSnZ2b1BHRHBtR2JyME9ia3J1YVlXZzBwTGVYWmx4Y0U3Q3JMTC14UGNod19RT2Y0VU5sTlJMdVZUX2ZZcHE0V21PM3U0cHZFRWRBWXQtSDc4N2xkeTFHY1VETWNwLXc?oc=5","date":"2018-05-23","type":"pipeline","source":"BioPharma Dive","summary":"AstraZeneca raising profile in Bay Area - BioPharma Dive","headline":"AstraZeneca raising profile in Bay Area","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRDVCWldWUlV6bF94dmNHU0Jvckh5UFI4UHRFY25DX3hqcEdKaFlWMjNCamxxMEVCNXJBUVlKWVZmNG81Z1dKSVR5LU1waHVqb1gwOWVxLXBiNGlQUVZnc2xURlJIMWhWYTJIVERkR2JaekdURGdMNFdHNzkzMVZKT2xMM2tSemZHaHBTVmxqMEVaV25tQTJoLXFFMGNpZnZpT3hXVzNFeHRWamh2NENsU2RWbFVzVGRX?oc=5","date":"2013-06-28","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca Completes Acquisition Of Pearl Therapeutics - AstraZeneca","headline":"AstraZeneca Completes Acquisition Of Pearl Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNOVY3d19LLXQ5Um1nbVlBemVBWTdnN2dObzRyMloydVZuSFZUV0RpYk8wSnR0Sk8zb0ZsbkNTckxjSm9kYWtEUGNJeG9JeWFOWldIMlZUdkwxZFRBcEZkWjU2MkkwS240dGRhbjF5aUUzUThQallVQTlYSHZ6TGROR1VUVUNkSzlOVG5VUkFyZS1fN3VOZHBzalVLTHdCMjFkX01jVTV2eFpkN2R4Z1hrSHM2bGt5RlowVExjeGlXUkRuV0E?oc=5","date":"2013-06-10","type":"deal","source":"AstraZeneca","summary":"AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio - AstraZeneca","headline":"AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio","sentiment":"neutral"}],"patents":[],"drugCount":21,"phaseCounts":{"phase_2":10,"phase_3":10,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}